Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Herpes simplex virus contributes to infertility in men

13 Jan 2018

In male partners of infertile couples, infection with herpes simplex virus (HSV) appears to exert a negative effect on two equally important components of semen, spermatozoa and seminal fluid, which may in turn influence fertility, as shown in a recent study.

Researchers examined a total of 279 semen samples from males aged ≥18 years. All men had a semen analysis due to fertility evaluation following a failure to conceive with their partner after 1 year of unprotected intercourse.

Basic seminal parameters were analysed, with HSV infection detected by multiplex polymerase chain reaction (M-PCR) assay.

M-PCR assay detected HSV in 10.7 percent of samples, of which 7.5 percent had HSV-1 exclusively and 3.2 percent had HSV-2 exclusively.

There were significant associations observed between HSV-2 infection and hematospermia and a lower mean seminal volume, and between HSV-1 infection and a lower mean sperm count.

“Further studies enrolling a larger number of patients are necessary to confirm [the present] data and to elucidate the clinical relevance of HSV presence in semen,” researchers said.

HSV-1 causes oral and occasionally genital cold sores, whereas HSV-2 is the most common cause of genital herpes. The effect of HSV on infertility may be caused by epididymal and prostatic function, as indicated by reduced concentrations of neutral α­glucosidase and citrate in HSV-positive semen samples. Notably, it has been shown that antiviral treatment (acyclovir and valacyclovir) can help HSV-positive, infertile male patients achieve pregnancy. [Nat Rev Urol 2014;11:672-687]

Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.